Audentes Therapeutics (BOLD) Tops Q1 EPS by 173c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of $0.71, $1.73 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Reading (RDI) Tops Q2 EPS by 4c